- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00193856
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
A Randomised Trial Investigating the Effect on Biochemical (PSA) Control and Survival of Different Durations of Adjuvant Androgen Deprivation in Association With Definitive Radiation Treatment for Localised Carcinoma of the Prostate.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Traditionally androgen deprivation (by orchidectomy, or more recently by medication) has been reserved for the palliative treatment of men with advanced, incurable prostate cancer. However, evidence from large scale trials is beginning to suggest that androgen deprivation (AD) may be helpful in preventing relapse in patients with more localised disease who are treated surgically or by radiotherapy. Of the 8000 patients per annum who are treated with curative intent, one half (4000) have cancers where 'adjuvant' AD may be prescribed according to interpretation of the registered indications. There are, however, enormous variations in prescribing practices which reflect uncertainty as to the appropriate indications. An important issue is osteopenia.
The increasing use of AD in men with earlier stages of cancer, whose life expectancies exceed 3 years, has exposed many unwanted metabolic sequelae of prolonged AD, the most important being osteopenia. In 1996, with the funding support of the NHMRC and the pharmaceutical industry, TROG therefore launched a large randomised three-arm trial. Two of the arms repeated the two arms of the US Radiation Therapy Oncology Group (RTOG) 86.01 trial which, at the time, was showing early indications of benefit for the addition of two months maximal androgen deprivation (MAD), using Goserelin (Zoladex) and Flutamide, before radiation therapy and one month during. Since work from Canada had indicated that continued AD for periods longer than three months produced additional shrinkage of the prostatic tumour, the TROG 96.01 trial incorporated a third arm: six months MAD prior to and during radiotherapy. The trial completed its recruitment target of 800 eligible patients in early 2000. Although in August 2001 the median follow up time was still very short, a preliminary analysis indicated that significant increases in time to biochemical relapse had been produced by AD. In fact, the benefits of AD were independent of stage, tumour grade and initial PSA value which were confirmed also to predict time to biochemical failure. The hazard of relapse reduced to 0.75 (0.55 - 0.97, 95% confidence intervals) with 3 months AD, and still further to 0.6 (0.45 - 0.82) with six months AD.
Subsequent international developments in this area of research encouraged the design of a 'follow on' trial. A European Organisation for Research and Treatment of Cancer (EORTC) trial reported that 3 years of adjuvant ('post hoc') AD (using Goserelin alone), administered after radiotherapy, reduced relapse and improved survival in patients with locally advanced prostate cancer. The US Radiation Therapy Oncology Group (RTOG) 85.31 trial indicated that indefinite Goserelin administration after radiotherapy reduced treatment failure rates at all sites when compared with radiotherapy alone. The RTOG 92.02 trial showed that 24 months of adjuvant Goserelin also reduced failure rates in patients treated with 4 months of MAD prior to and during radiotherapy. Subset analyses of the RTOG trials, suggested that patients who gain most from prolonged AD in terms of survival are those with high grade cancers.
It was therefore logical for TROG to propose a second trial with the intention of finding out whether an additional 12 months of AD administered after radiotherapy (aka 'intermediate term' AD [ITAD]) would reduce relapse and mortality in patients treated with six months of AD prior to and during radiotherapy (aka 'short term' AD [STAD]) as in the 'best' arm of its first (96.01) trial. The availability of the potent bisphosphonate, zoledronic acid, also made it possible to find out whether or not osteopenia induced in the two arms of the proposed second trial would be prevented by a second random assignment to 18 months' bisphosphonate therapy (BP).
This is a randomised phase III multicentre clinical trial.
After informed consent is given and eligibility is checked patients will be randomised to one of four trial arms:
- 6 months of androgen blockade with an LH-RH analogue (5 months before start of radiotherapy) (STAD),
- 18 months of androgen blockade with an LH-RH analogue (starting 5 months before start of radiotherapy) (ITAD),
- 18 months of therapy with zoledronic acid 4 mg by intravenous infusion every 3 months for 18 months beginning concurrently with STAD
- 18 months of therapy with zoledronic acid beginning concurrently with ITAD.
Stratification will be according to the following criteria:
T2 / T3, 4 Gleason score 2 - 6 / 7+ Presenting PSA <10 / 10 - 20 / >20 Treatment centre
Radiation Treatment will be delivered using a conventional technique, unless the treatment centre of the participating clinician demonstrates an ability to deliver the treatment using a CRT, IMRT, or HDRB technique verified by the trial TACT.
Drug Treatment:
LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an Intramuscular injection (IMI).
Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to this therapy. No placebo therapy will be given to patients randomised to 'no bisphosphonate therapy' treatment arm.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Campbelltown, New South Wales, Australië, 2560
- Campbelltown Hospital
-
Kogarah, New South Wales, Australië, 2217
- St George Hospital
-
Lismore, New South Wales, Australië, 2480
- Lismore Hospital
-
Liverpool, New South Wales, Australië, 1871
- Liverpool Hospital
-
Newcastle, New South Wales, Australië, 2298
- Calvary Mater Newcastle
-
Penrith, New South Wales, Australië, 2751
- Nepean Cancer Care Centre
-
Sydney, New South Wales, Australië, 2069
- Royal North Shore Hospital
-
Wagga Wagga, New South Wales, Australië, 2650
- Riverina Cancer Care Centre
-
Wentworthville, New South Wales, Australië, 2145
- Westmead Hospital
-
Wollongong, New South Wales, Australië
- Illawarra Cancer Care Centre
-
-
Queensland
-
Herston, Queensland, Australië, 4029
- Royal Brisbane Hospital
-
South Brisbane, Queensland, Australië, 4101
- Mater QRI
-
Tugun, Queensland, Australië, 4224
- John Flynn Private Hospital
-
Woolloongabba, Queensland, Australië, 4102
- Princess Alexandra Hospital
-
-
Tasmania
-
Launceston, Tasmania, Australië, 7250
- Launceston General Hospital
-
-
Victoria
-
East Melbourne, Victoria, Australië, 8006
- Peter MacCallum Cancer Centre
-
Geelong, Victoria, Australië, 3220
- Andrew Love Cancer Care Centre, Geelong Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Auckland, Nieuw-Zeeland, 1001
- Auckland Hospital
-
Christchurch, Nieuw-Zeeland, 4710
- Christchurch Hospital
-
Dunedin, Nieuw-Zeeland
- Dunedin Hospital
-
Hamilton, Nieuw-Zeeland, 3200
- Waikato Hospital
-
Palmerston North, Nieuw-Zeeland
- Palmerston North Hospital
-
Wellington, Nieuw-Zeeland, 7902
- Wellington Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histological confirmation of adenocarcinoma of the prostate in the three months prior to randomisation
- Gleason primary and secondary pattern reported. If the volume of tumour in biopsies is too small for the pathologist to allocate a secondary pattern, the primary pattern alone is sufficient.
- Primary tumour stage T2b - 4 (UICC 2002), or T2a providing biopsies demonstrate Gleason score 7 or more, and presenting PSA 10 or more
- PSA value obtained within one month of randomisation
- No evidence of lymphatic or haematogenous metastases, as determined by negative chest x-ray, CT scan of abdomen and pelvis, and bone scan in the 3 months prior to randomisation
- ECOG performance status 0 - 1
- No concurrent medical conditions likely to significantly reduce prospects of 5 year survival
- Patient accessible to follow up at intervals specified in protocol
- Written informed consent given (signed by both patient and investigator prior to randomisation)
Exclusion Criteria:
- Previous or concurrent malignancy within previous 5 years except for non-melanomatous skin cancer
- Prostatectomy
- Prior pelvic radiotherapy
- Prior hormone treatment for prostate cancer
- Inability to complete self administered QOL questionnaire
- Prior bisphosphonate therapy
- Serum creatinine > 2 x ULN
- Osteoporosis resulting in >30% loss in vertebral height in one or more thoraco-lumbar vertebrae
- Liver disease resulting in ALT or AST levels >3 x ULN
- Prolonged continuous glucocorticoid therapy > 10 mg/day of prednisone equivalent (>6 months)
- Current treatment with bisphosphonate
- Inability to attend for follow-up at the Investigator's clinic
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Faculteitstoewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: A
LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
|
LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months.
This will be administered as an intramuscular injection (IMI).
The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
|
Actieve vergelijker: B
LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
|
LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months.
This will be administered as an intramuscular injection (IMI).
The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
|
Experimenteel: C
LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
|
LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months.
This will be administered as an intramuscular injection (IMI).
The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
|
Experimenteel: D
LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.
|
LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months.
This will be administered as an intramuscular injection (IMI).
The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Prostate cancer-specific mortality.
Tijdsspanne: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant
|
Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Cumulative incidence of PSA progression
Tijdsspanne: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant
|
Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant
|
Cumulative incidence of local, distant and bony progression and associated patterns of clinical progression
Tijdsspanne: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant
|
Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant
|
All-cause mortality
Tijdsspanne: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant
|
Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant
|
Changes in bone mineral density and osteopenic fracture
Tijdsspanne: One endpoint analysis is planned when 4.5 years have elapsed from randomisation of the last participant
|
One endpoint analysis is planned when 4.5 years have elapsed from randomisation of the last participant
|
Quality of life assessment
Tijdsspanne: One endpoint analysis is planned when 3 years have elapsed from randomisation of the last participant
|
One endpoint analysis is planned when 3 years have elapsed from randomisation of the last participant
|
Treatment related morbidity
Tijdsspanne: One endpoint analysis is planned when 4 years have elapsed from randomisation of the last participant
|
One endpoint analysis is planned when 4 years have elapsed from randomisation of the last participant
|
Cumulative incidence of secondary therapeutic intervention
Tijdsspanne: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomization of the last participant
|
Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomization of the last participant
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie stoel: Jim Denham, FRANZCR, University of Newcastle, Australia
Publicaties en nuttige links
Algemene publicaties
- Haworth A, Kearvell R, Greer PB, Hooton B, Denham JW, Lamb D, Duchesne G, Murray J, Joseph D. Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study. Radiother Oncol. 2009 Mar;90(3):299-306. doi: 10.1016/j.radonc.2008.10.011. Epub 2008 Nov 18.
- Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2019 Feb;20(2):267-281. doi: 10.1016/S1470-2045(18)30757-5. Epub 2018 Dec 19.
- Moulton CR, House MJ, Lye V, Tang CI, Krawiec M, Joseph DJ, Denham JW, Ebert MA. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol. 2016 Oct 31;11(1):144. doi: 10.1186/s13014-016-0719-2.
- Denham JW, Steigler A, Joseph D, Lamb DS, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai KH, Gogna NK, Gill S, Tan H, Kearvell R, Murray J, Ebert M, Haworth A, Kennedy A, Delahunt B, Oldmeadow C, Holliday EG, Attia J. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiother Oncol. 2015 Jun;115(3):301-7. doi: 10.1016/j.radonc.2015.05.016. Epub 2015 Jun 10.
- Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.
- Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol. 2012 Dec;13(12):1260-70. doi: 10.1016/S1470-2045(12)70423-0. Epub 2012 Nov 12. Erratum In: Lancet Oncol. 2014 Sep;15(10):e417. Dosage error in article text.
- Denham JW, Wilcox C, Lamb DS, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai KH, Gogna NK, Ebert M, Delahunt B, McElduff P, Joseph D. Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiother Oncol. 2012 Nov;105(2):184-92. doi: 10.1016/j.radonc.2012.09.018. Epub 2012 Nov 3.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Urogenitale neoplasmata
- Neoplasmata per site
- Genitale neoplasmata, mannelijk
- Prostaat Ziekten
- Prostaatneoplasmata
- Fysiologische effecten van medicijnen
- Antineoplastische middelen
- Antineoplastische middelen, hormonaal
- Behoudsmiddelen voor botdichtheid
- Reproductieve controlemiddelen
- Vruchtbaarheidsmiddelen, vrouwelijk
- Vruchtbaarheid agenten
- Leuprolide
- Zoledroninezuur
Andere studie-ID-nummers
- TROG 03.04
- ACTRN12607000097448 (Register-ID: Australian New Zealand Clinical Trials Registry)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Prostaatkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten